Monday - June 9, 2025
TAMPA, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- FLUENT Corp. (CSE: FNT.U) (OTCQB: CNTMF) ("FLUENT" or the "Company"), a vertically-integrated, multi-state cannabis company, today announced its financial and operating results for the first quarter ended March 31, 2025. Unless otherwise indicated, all financial results are presented in U.S. dollars.
Management Commentary
“In Q1 2025, we generated $26.7 million in revenue, a 5.9% increase year-over-year, despite continued price compression and increased market saturation in Florida,” said Robert Beasley, Chief Executive Officer of FLUENT. “While adjusted EBITDA declined to $3.5 million, largely due to softness in Florida, our core fundamentals remain strong. We continue to invest in infrastructure and brand development to support long-term growth. Despite industry-wide challenges this quarter, we remained focused on disciplined execution.”
Beasley added, “In New York, integration of the RIV Capital assets is progressing well, with the Buffalo cultivation facility nearing completion and the FLUENT retail rebrand underway. In Florida, we launched new products and completed construction of the Roza facility, expanding production capacity ahead of our next planned harvest. Our cash position of $30.7 million, up from $8.5 million a year ago, gives us the flexibility to support near-term priorities and long-term growth.”
He concluded, “While macro and regulatory uncertainties remain, we are focused on strengthening our core markets, managing costs, and positioning the company to adapt and grow as market conditions evolve.”
Q1 2025 Financial Highlights (vs. Q1 2024)
Recent Operational Highlights
Company Footprint:
Florida:
New York:
Texas:
Pennsylvania:
The company is actively monitoring legislative developments and is encouraged by the accelerating momentum toward adult-use legalization in Pennsylvania and the potential expansion of the medical program in Texas, both of which represent promising future growth catalysts.
_____________________________
1 Gross profit before fair value adjustments is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates gross profit before fair value adjustments from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations.
Conference Call
The Company will host a conference call and live audio webcast today at 4:30 p.m. Eastern time to discuss its financial and operational results, followed by a question-and-answer period.
Date: Thursday, May 29, 2025
Time: 4:30 p.m. Eastern time
Toll-free dial-in number: 1-844-763-8274 (toll -free)
International dial-in number: 1-412-717-9224 (international)
Join Instructions: Participants to ask to be joined into the FLUENT Corp. call.
Link: FLUENT Corp Conference Call
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization.
The conference call will also be available for replay for up to two weeks via the News & Events section of the Company’s investor relations website at https://investors.getFLUENT.com/.
Forward-Looking Information
Certain information in this news release may constitute forward-looking information within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent the Company's expectations, estimates, and projections regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control.
Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available on its SEDAR+ profile at www.sedarplus.ca. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
For further information visit: https://getfluent.com/ and https://investors.getFLUENT.com/
Investor Relations Contact
investors@getFLUENT.com
Media Contact:
press@getfluent.com
Officer Contact:
Robert Beasley, CEO
(850) 972-8077
Fluent Corp. | |||||||
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | |||||||
As of March 31, 2025 and December 31, 2024 | |||||||
(USD '000) | |||||||
March 31, 2025 | December 31, 2024 | ||||||
Assets | |||||||
Current assets | |||||||
Cash and cash equivalents | $ | 30,744 | $ | 40,106 | |||
Accounts receivable | 235 | 422 | |||||
Biological assets | 3,298 | 3,162 | |||||
Inventory, net | 20,051 | 15,155 | |||||
Prepaid expenses and other current assets | 1,824 | 2,587 | |||||
Total current assets | $ | 56,152 | $ | 61,432 | |||
Property and equipment, net | 53,757 | 52,200 | |||||
Intangible assets, net | 37,315 | 37,590 | |||||
Right-of-use assets, net | 45,523 | 46,731 | |||||
Goodwill | 1,525 | 1,525 | |||||
Deferred tax assets | 1,248 | 1,039 | |||||
Other assets | 6,534 | 6,476 | |||||
Total assets | $ | 202,053 | $ | 206,992 | |||
Liabilities and shareholders' equity | |||||||
Current liabilities | |||||||
Accounts payable | $ | 4,439 | $ | 6,331 | |||
Accrued expenses | 8,923 | 8,423 | |||||
Income taxes payable | 1,003 | 1,003 | |||||
Derivative liabilities | 1,691 | 2,148 | |||||
Short term provision liability | 5,000 | 4,957 | |||||
Current portion of notes payable | 458 | 755 | |||||
Lease obligations - current portion | 4,943 | 4,751 | |||||
Total current liabilities | $ | 26,457 | $ | 28,368 | |||
Long-term liabilities | |||||||
Notes payable, net of current portion and financing costs | 69,261 | 68,775 | |||||
Lease obligations, net of current portion | 51,168 | 51,727 | |||||
Deferred tax liability | 5,542 | 4,817 | |||||
Uncertain tax position | 48,176 | 43,314 | |||||
Long term provision liability | 8,980 | 9,044 | |||||
Convertible notes, net | 6,729 | 6,482 | |||||
Other long-term liabilities | 3,447 | 3,447 | |||||
Total long-term liabilities | $ | 193,303 | $ | 187,606 | |||
Total liabilities | $ | 219,760 | $ | 215,974 | |||
Shareholders' equity | |||||||
Share capital | 206,419 | 206,419 | |||||
Share-based compensation reserve | 7,300 | 7,275 | |||||
Equity conversion feature | 7,097 | 7,097 | |||||
Warrants | 29,634 | 29,634 | |||||
Accumulated deficit | (266,961 | ) | (258,211 | ) | |||
Accumulated other comprehensive income (loss) | (1,196 | ) | (1,196 | ) | |||
Total shareholders' equity | (17,707 | ) | (8,982 | ) | |||
Total liabilities and shareholders' equity | $ | 202,053 | $ | 206,992 | |||
Fluent Corp. | |||||||
CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) | |||||||
For the three months ended March 31, 2025 and March 31, 2024 | |||||||
(USD '000) | For the three months ended | ||||||
March 31, 2025 | March 31, 2024 | ||||||
Revenue, net | $ | 26,717 | $ | 25,227 | |||
Cost of goods sold | 14,195 | 12,966 | |||||
Gross profit before fair value adjustments | 12,522 | 12,261 | |||||
Fair value adjustments on inventory sold | (301 | ) | 1,628 | ||||
Unrealized gain (loss) on changes in fair value of biological assets | 3,025 | 1,047 | |||||
Gross profit | 15,246 | 14,936 | |||||
Operating expenses: | |||||||
General and administrative | 4,894 | 3,963 | |||||
Sales and marketing | 6,319 | 5,434 | |||||
Depreciation and amortization | 2,025 | 1,730 | |||||
Share-based compensation | 25 | 49 | |||||
Total operating expenses | 13,263 | 11,176 | |||||
Income from operations | 1,982 | 3,760 | |||||
Other expense (income): | |||||||
Finance costs, net | 4,423 | 4,711 | |||||
Gain on change in fair value of derivative liability | (457 | ) | (1,687 | ) | |||
Loss on disposal of assets | - | 212 | |||||
Other expense, net | 12 | 2 | |||||
Total other expense | 3,978 | 3,238 | |||||
Net income (loss) before income taxes | (1,996 | ) | 522 | ||||
Income tax expense | 6,754 | 4,685 | |||||
Comprehensive income (loss) | $ | (8,750 | ) | $ | (4,163 | ) | |
Net loss per share - basic and diluted | $ | (0.02 | ) | $ | (0.01 | ) | |
Fluent Corp. | |||||||
CONSOLIDATED STATEMENTS OF CASH FLOW | |||||||
For the three months ended March 31, 2025 and March 31, 2024 | |||||||
(USD '000) | |||||||
For the three months ended | |||||||
March 31, 2025 | March 31, 2024 | ||||||
Cash flows used in operating activities | |||||||
Net loss | $ | (8,750 | ) | $ | (4,163 | ) | |
Adjustments for non-cash items: | |||||||
Bargain purchase gain on business combination | |||||||
Loss on issuance and extinguishment of debt instruments, net | |||||||
Intangible assets impairment | |||||||
Unrealized (gain) loss on changes in fair value of biological assets | (3,025 | ) | (1,047 | ) | |||
Realized (gain) loss on fair value amounts included in inventory sold | 301 | (1,628 | ) | ||||
Share-based compensation expense | 25 | 49 | |||||
Depreciation and amortization | 4,553 | 3,703 | |||||
Accretion and interest expense | 4,332 | 4,686 | |||||
Net change in fair value of derivative | (457 | ) | (1,687 | ) | |||
Loss on dispositions of fixed assets | - | 212 | |||||
Uncertain tax position | 4,862 | - | |||||
Deferred tax expense | 516 | 1,216 | |||||
Changes in non-cash working capital | |||||||
Accounts receivable | 187 | (17 | ) | ||||
Inventory | 3,279 | 3,939 | |||||
Biological assets | (5,587 | ) | (3,551 | ) | |||
Prepaid expenses and other current assets | 763 | 747 | |||||
Right of use assets / liabilities | (1,000 | ) | (1,317 | ) | |||
Other assets | (58 | ) | (90 | ) | |||
Accounts payable | (1,892 | ) | 630 | ||||
Accrued expenses | 500 | (4,192 | ) | ||||
Income taxes | - | 6,938 | |||||
Other long-term liabilities | - | (375 | ) | ||||
Net cash provided by operating activities | $ | (1,451 | ) | $ | 4,053 | ||
Cash flows used in investing activities | |||||||
Purchase of property and equipment | $ | (4,179 | ) | $ | (2,948 | ) | |
Net cash provided by used in investing activities | $ | (4,179 | ) | $ | (2,948 | ) | |
Cash flows provided by used in financing activities | |||||||
Principal repayments of notes payable | (2,681 | ) | (2,340 | ) | |||
Payment of lease obligations | (1,051 | ) | (765 | ) | |||
Net cash used in financing activities | $ | (3,732 | ) | $ | (3,105 | ) | |
Net decrease in cash and cash equivalents | $ | (9,362 | ) | $ | (2,000 | ) | |
Cash, beginning of period | 40,106 | 10,521 | |||||
Cash, end of period | $ | 30,744 | $ | 8,521 | |||
Fluent Corp. | |||||||
EBITDA AND ADJUSTED EBITDA CALCULATION | |||||||
For the three months ended March 31, 2025 and March 31, 2024 | |||||||
(USD '000) | |||||||
For the three months ended | |||||||
March 31, 2025 | March 31, 2024 | ||||||
Net loss | $ | (8,750 | ) | $ | (4,163 | ) | |
Finance costs, net | 4,423 | 4,711 | |||||
Income taxes | 6,754 | 4,685 | |||||
Depreciation and amortization | 4,014 | 3,702 | |||||
EBITDA | $ | 6,441 | $ | 8,935 | |||
For the three months ended | |||||||
March 31, 2025 | March 31, 2024 | ||||||
EBITDA | $ | 6,441 | $ | 8,935 | |||
Change in fair value of biological assets | (2,724 | ) | (2,675 | ) | |||
Change in fair market value of derivative | (457 | ) | (1,687 | ) | |||
Professional fees(1) | 74 | 1,789 | |||||
One-time employee costs(2) | 133 | 160 | |||||
Share-based compensation | 25 | 49 | |||||
Loss on disposal of assets | - | 212 | |||||
Other non-recurring expense | 12 | 2 | |||||
Adjusted EBITDA | $ | 3,504 | $ | 6,785 | |||
(1) Legal and professional fees associated with potential transactions and professional fees associated with prior periods. | |||||||
(2) Severance and relocation costs. | |||||||
Last Trade: | US$0.05 |
Daily Change: | -0.001 -2.00 |
Daily Volume: | 36,874 |
Market Cap: | US$21.940M |
June 03, 2025 May 20, 2025 May 12, 2025 |
COPYRIGHT ©2025 GREEN STOCK NEWS